secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001213900-23-030851
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics updates corporate presentation, no financial data disclosed
--------------------------------------------------------------------------------

- Filed 8-K on April 19, 2023, to announce an updated corporate presentation.
- Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders' filed as Exhibit 99.1.
- No specific financial or operational milestones provided in the filing or exhibit text.
- CEO Sergio Traversa signed the filing; presentation may contain pipeline or strategy updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/0001213900-23-030851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/ea177149-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-030851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer